The global Pulmonary Drug Delivery Systems market size was valued at US$ 3277 million in 2024 and is forecast to a readjusted size of USD 4329 million by 2031 with a CAGR of 4.1% during review period.
Pulmonary drug delivery systems are used to the treatment of various respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD), delivering locally acting drugs directly to their site of action. Advantages of pulmonary drug delivery systems over oral drugs is the excellent capability of absorbing pharmaceuticals, due to the large absorptive surface area of lungs (approximately 70-140 m2 in adult humans having extremely thin absorptive mucosal membrane) and good blood supply.
The major players in global Pulmonary Drug Delivery Systems market include 3M, GSK, AstraZeneca, etc. The top 3 players occupy about 60% shares of the global market. Europe and North America are main markets, they occupy over 75% of the global market. Metered Dose Inhaler (MDI) is the main type, with a share over 60%. COPD is the main application, which holds a share over 50%.
This report is a detailed and comprehensive analysis for global Pulmonary Drug Delivery Systems market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Pulmonary Drug Delivery Systems market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global Pulmonary Drug Delivery Systems market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global Pulmonary Drug Delivery Systems market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2020-2031
Global Pulmonary Drug Delivery Systems market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Pulmonary Drug Delivery Systems
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Pulmonary Drug Delivery Systems market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include 3M, GSK, AstraZeneca, Cipla, Chiesi, Boehringer Ingelheim, Aptar, Novartis, Philips Respironics, Omron Healthcare, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
Pulmonary Drug Delivery Systems market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Nebulizers
Dry Powder Inhaler (DPI)
Metered Dose Inhaler (MDI)
麻豆原创 segment by Application
COPD
Asthma
Others
Major players covered
3M
GSK
AstraZeneca
Cipla
Chiesi
Boehringer Ingelheim
Aptar
Novartis
Philips Respironics
Omron Healthcare
PARI
Skyepharma
CareFusion
Shanghai Huarui
Taian Character
Chia Tai Tianqing
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Pulmonary Drug Delivery Systems product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Pulmonary Drug Delivery Systems, with price, sales quantity, revenue, and global market share of Pulmonary Drug Delivery Systems from 2020 to 2025.
Chapter 3, the Pulmonary Drug Delivery Systems competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Pulmonary Drug Delivery Systems breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Pulmonary Drug Delivery Systems market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Pulmonary Drug Delivery Systems.
Chapter 14 and 15, to describe Pulmonary Drug Delivery Systems sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Pulmonary Drug Delivery Systems Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Nebulizers
1.3.3 Dry Powder Inhaler (DPI)
1.3.4 Metered Dose Inhaler (MDI)
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Pulmonary Drug Delivery Systems Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 COPD
1.4.3 Asthma
1.4.4 Others
1.5 Global Pulmonary Drug Delivery Systems 麻豆原创 Size & Forecast
1.5.1 Global Pulmonary Drug Delivery Systems Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Pulmonary Drug Delivery Systems Sales Quantity (2020-2031)
1.5.3 Global Pulmonary Drug Delivery Systems Average Price (2020-2031)
2 Manufacturers Profiles
2.1 3M
2.1.1 3M Details
2.1.2 3M Major Business
2.1.3 3M Pulmonary Drug Delivery Systems Product and Services
2.1.4 3M Pulmonary Drug Delivery Systems Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 3M Recent Developments/Updates
2.2 GSK
2.2.1 GSK Details
2.2.2 GSK Major Business
2.2.3 GSK Pulmonary Drug Delivery Systems Product and Services
2.2.4 GSK Pulmonary Drug Delivery Systems Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 GSK Recent Developments/Updates
2.3 AstraZeneca
2.3.1 AstraZeneca Details
2.3.2 AstraZeneca Major Business
2.3.3 AstraZeneca Pulmonary Drug Delivery Systems Product and Services
2.3.4 AstraZeneca Pulmonary Drug Delivery Systems Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 AstraZeneca Recent Developments/Updates
2.4 Cipla
2.4.1 Cipla Details
2.4.2 Cipla Major Business
2.4.3 Cipla Pulmonary Drug Delivery Systems Product and Services
2.4.4 Cipla Pulmonary Drug Delivery Systems Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Cipla Recent Developments/Updates
2.5 Chiesi
2.5.1 Chiesi Details
2.5.2 Chiesi Major Business
2.5.3 Chiesi Pulmonary Drug Delivery Systems Product and Services
2.5.4 Chiesi Pulmonary Drug Delivery Systems Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Chiesi Recent Developments/Updates
2.6 Boehringer Ingelheim
2.6.1 Boehringer Ingelheim Details
2.6.2 Boehringer Ingelheim Major Business
2.6.3 Boehringer Ingelheim Pulmonary Drug Delivery Systems Product and Services
2.6.4 Boehringer Ingelheim Pulmonary Drug Delivery Systems Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Boehringer Ingelheim Recent Developments/Updates
2.7 Aptar
2.7.1 Aptar Details
2.7.2 Aptar Major Business
2.7.3 Aptar Pulmonary Drug Delivery Systems Product and Services
2.7.4 Aptar Pulmonary Drug Delivery Systems Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Aptar Recent Developments/Updates
2.8 Novartis
2.8.1 Novartis Details
2.8.2 Novartis Major Business
2.8.3 Novartis Pulmonary Drug Delivery Systems Product and Services
2.8.4 Novartis Pulmonary Drug Delivery Systems Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Novartis Recent Developments/Updates
2.9 Philips Respironics
2.9.1 Philips Respironics Details
2.9.2 Philips Respironics Major Business
2.9.3 Philips Respironics Pulmonary Drug Delivery Systems Product and Services
2.9.4 Philips Respironics Pulmonary Drug Delivery Systems Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Philips Respironics Recent Developments/Updates
2.10 Omron Healthcare
2.10.1 Omron Healthcare Details
2.10.2 Omron Healthcare Major Business
2.10.3 Omron Healthcare Pulmonary Drug Delivery Systems Product and Services
2.10.4 Omron Healthcare Pulmonary Drug Delivery Systems Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 Omron Healthcare Recent Developments/Updates
2.11 PARI
2.11.1 PARI Details
2.11.2 PARI Major Business
2.11.3 PARI Pulmonary Drug Delivery Systems Product and Services
2.11.4 PARI Pulmonary Drug Delivery Systems Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 PARI Recent Developments/Updates
2.12 Skyepharma
2.12.1 Skyepharma Details
2.12.2 Skyepharma Major Business
2.12.3 Skyepharma Pulmonary Drug Delivery Systems Product and Services
2.12.4 Skyepharma Pulmonary Drug Delivery Systems Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.12.5 Skyepharma Recent Developments/Updates
2.13 CareFusion
2.13.1 CareFusion Details
2.13.2 CareFusion Major Business
2.13.3 CareFusion Pulmonary Drug Delivery Systems Product and Services
2.13.4 CareFusion Pulmonary Drug Delivery Systems Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.13.5 CareFusion Recent Developments/Updates
2.14 Shanghai Huarui
2.14.1 Shanghai Huarui Details
2.14.2 Shanghai Huarui Major Business
2.14.3 Shanghai Huarui Pulmonary Drug Delivery Systems Product and Services
2.14.4 Shanghai Huarui Pulmonary Drug Delivery Systems Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.14.5 Shanghai Huarui Recent Developments/Updates
2.15 Taian Character
2.15.1 Taian Character Details
2.15.2 Taian Character Major Business
2.15.3 Taian Character Pulmonary Drug Delivery Systems Product and Services
2.15.4 Taian Character Pulmonary Drug Delivery Systems Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.15.5 Taian Character Recent Developments/Updates
2.16 Chia Tai Tianqing
2.16.1 Chia Tai Tianqing Details
2.16.2 Chia Tai Tianqing Major Business
2.16.3 Chia Tai Tianqing Pulmonary Drug Delivery Systems Product and Services
2.16.4 Chia Tai Tianqing Pulmonary Drug Delivery Systems Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.16.5 Chia Tai Tianqing Recent Developments/Updates
3 Competitive Environment: Pulmonary Drug Delivery Systems by Manufacturer
3.1 Global Pulmonary Drug Delivery Systems Sales Quantity by Manufacturer (2020-2025)
3.2 Global Pulmonary Drug Delivery Systems Revenue by Manufacturer (2020-2025)
3.3 Global Pulmonary Drug Delivery Systems Average Price by Manufacturer (2020-2025)
3.4 麻豆原创 Share Analysis (2024)
3.4.1 Producer Shipments of Pulmonary Drug Delivery Systems by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2024
3.4.2 Top 3 Pulmonary Drug Delivery Systems Manufacturer 麻豆原创 Share in 2024
3.4.3 Top 6 Pulmonary Drug Delivery Systems Manufacturer 麻豆原创 Share in 2024
3.5 Pulmonary Drug Delivery Systems 麻豆原创: Overall Company Footprint Analysis
3.5.1 Pulmonary Drug Delivery Systems 麻豆原创: Region Footprint
3.5.2 Pulmonary Drug Delivery Systems 麻豆原创: Company Product Type Footprint
3.5.3 Pulmonary Drug Delivery Systems 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Pulmonary Drug Delivery Systems 麻豆原创 Size by Region
4.1.1 Global Pulmonary Drug Delivery Systems Sales Quantity by Region (2020-2031)
4.1.2 Global Pulmonary Drug Delivery Systems Consumption Value by Region (2020-2031)
4.1.3 Global Pulmonary Drug Delivery Systems Average Price by Region (2020-2031)
4.2 North America Pulmonary Drug Delivery Systems Consumption Value (2020-2031)
4.3 Europe Pulmonary Drug Delivery Systems Consumption Value (2020-2031)
4.4 Asia-Pacific Pulmonary Drug Delivery Systems Consumption Value (2020-2031)
4.5 South America Pulmonary Drug Delivery Systems Consumption Value (2020-2031)
4.6 Middle East & Africa Pulmonary Drug Delivery Systems Consumption Value (2020-2031)
5 麻豆原创 Segment by Type
5.1 Global Pulmonary Drug Delivery Systems Sales Quantity by Type (2020-2031)
5.2 Global Pulmonary Drug Delivery Systems Consumption Value by Type (2020-2031)
5.3 Global Pulmonary Drug Delivery Systems Average Price by Type (2020-2031)
6 麻豆原创 Segment by Application
6.1 Global Pulmonary Drug Delivery Systems Sales Quantity by Application (2020-2031)
6.2 Global Pulmonary Drug Delivery Systems Consumption Value by Application (2020-2031)
6.3 Global Pulmonary Drug Delivery Systems Average Price by Application (2020-2031)
7 North America
7.1 North America Pulmonary Drug Delivery Systems Sales Quantity by Type (2020-2031)
7.2 North America Pulmonary Drug Delivery Systems Sales Quantity by Application (2020-2031)
7.3 North America Pulmonary Drug Delivery Systems 麻豆原创 Size by Country
7.3.1 North America Pulmonary Drug Delivery Systems Sales Quantity by Country (2020-2031)
7.3.2 North America Pulmonary Drug Delivery Systems Consumption Value by Country (2020-2031)
7.3.3 United States 麻豆原创 Size and Forecast (2020-2031)
7.3.4 Canada 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Mexico 麻豆原创 Size and Forecast (2020-2031)
8 Europe
8.1 Europe Pulmonary Drug Delivery Systems Sales Quantity by Type (2020-2031)
8.2 Europe Pulmonary Drug Delivery Systems Sales Quantity by Application (2020-2031)
8.3 Europe Pulmonary Drug Delivery Systems 麻豆原创 Size by Country
8.3.1 Europe Pulmonary Drug Delivery Systems Sales Quantity by Country (2020-2031)
8.3.2 Europe Pulmonary Drug Delivery Systems Consumption Value by Country (2020-2031)
8.3.3 Germany 麻豆原创 Size and Forecast (2020-2031)
8.3.4 France 麻豆原创 Size and Forecast (2020-2031)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Russia 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Italy 麻豆原创 Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific Pulmonary Drug Delivery Systems Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Pulmonary Drug Delivery Systems Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Pulmonary Drug Delivery Systems 麻豆原创 Size by Region
9.3.1 Asia-Pacific Pulmonary Drug Delivery Systems Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Pulmonary Drug Delivery Systems Consumption Value by Region (2020-2031)
9.3.3 China 麻豆原创 Size and Forecast (2020-2031)
9.3.4 Japan 麻豆原创 Size and Forecast (2020-2031)
9.3.5 South Korea 麻豆原创 Size and Forecast (2020-2031)
9.3.6 India 麻豆原创 Size and Forecast (2020-2031)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2020-2031)
9.3.8 Australia 麻豆原创 Size and Forecast (2020-2031)
10 South America
10.1 South America Pulmonary Drug Delivery Systems Sales Quantity by Type (2020-2031)
10.2 South America Pulmonary Drug Delivery Systems Sales Quantity by Application (2020-2031)
10.3 South America Pulmonary Drug Delivery Systems 麻豆原创 Size by Country
10.3.1 South America Pulmonary Drug Delivery Systems Sales Quantity by Country (2020-2031)
10.3.2 South America Pulmonary Drug Delivery Systems Consumption Value by Country (2020-2031)
10.3.3 Brazil 麻豆原创 Size and Forecast (2020-2031)
10.3.4 Argentina 麻豆原创 Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa Pulmonary Drug Delivery Systems Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Pulmonary Drug Delivery Systems Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Pulmonary Drug Delivery Systems 麻豆原创 Size by Country
11.3.1 Middle East & Africa Pulmonary Drug Delivery Systems Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Pulmonary Drug Delivery Systems Consumption Value by Country (2020-2031)
11.3.3 Turkey 麻豆原创 Size and Forecast (2020-2031)
11.3.4 Egypt 麻豆原创 Size and Forecast (2020-2031)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2020-2031)
11.3.6 South Africa 麻豆原创 Size and Forecast (2020-2031)
12 麻豆原创 Dynamics
12.1 Pulmonary Drug Delivery Systems 麻豆原创 Drivers
12.2 Pulmonary Drug Delivery Systems 麻豆原创 Restraints
12.3 Pulmonary Drug Delivery Systems Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Pulmonary Drug Delivery Systems and Key Manufacturers
13.2 Manufacturing Costs Percentage of Pulmonary Drug Delivery Systems
13.3 Pulmonary Drug Delivery Systems Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Pulmonary Drug Delivery Systems Typical Distributors
14.3 Pulmonary Drug Delivery Systems Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
3M
GSK
AstraZeneca
Cipla
Chiesi
Boehringer Ingelheim
Aptar
Novartis
Philips Respironics
Omron Healthcare
PARI
Skyepharma
CareFusion
Shanghai Huarui
Taian Character
Chia Tai Tianqing
听
听
*If Applicable.
